Tagged with EU

China A summary of top stories from China’s pharma industry: Sciwind Biosciences presents promising trial data for its obesity contender; Simcere reaches approval for its Idorsia-partnered insomnia therapy; AstraZeneca inks AI-enabled research deal with CSPC Pharmaceuticals, and the FDA blocks clinical trials that export American’s cells to China. Sciwind’s GLP‑1 data…

Switzerland Neurim Pharmaceuticals is a research-driven pharmaceutical company dedicated to advancing science in central nervous system disorders, with a strong emphasis on sleep-related conditions. Carolin Hillebrand, Country Manager of Switzerland and Regional Alliance Lead for the German market, shares the company’s recent achievements including the development, regulatory approval, and commercialisation of…

Europe Writing in the June 2025 edition of DIA’s Global Forum Magazine, Finn McCartney, Maria Dutarte, Petra Adámková, and Paola Kruger from the European Patients’ Academy on Therapeutic Innovation (EUPATI) weigh in on how the patient voice is being incorporated into Joint Clinical Assessments (JCA) under the new EU Health Technology…

Germany Once a little-known mRNA pioneer, BioNTech became a household name with its COVID-19 vaccine developed alongside Pfizer. But the German biotech is now pursuing an even bigger transformation — and China is at the heart of its strategy. Using vaccine proceeds to tap China’s booming life sciences ecosystem, BioNTech has…

Switzerland Amid a crowded landscape of incremental innovation, Synendos Therapeutics stands out for its bold approach to neuropsychiatric drug development. Co-Founder and CEO Andrea Chicca shares how the company emerged from a translational research programme in Switzerland to pioneer a first-in-class therapeutic strategy targeting the endocannabinoid system, a master regulator of…

Europe Lora Fleifel, Director of Global Value Access & Pricing Operations Europe for Oncology at Merck, dissects the promise and pitfalls of the new EU Joint Clinical Assessment (JCA). The JCA aims to harmonise clinical evaluations to help reduce the significant disparities in patient access to innovative treatments that still exist…

Denmark As Denmark launches its ambitious Life Science Strategy 2030, the Danish Medicines Agency (DKMA), long held as the embodiment of European regulatory excellence, is fine-tuning its priorities. New director Nils Falk Bjerregaard sees the DKMA’s role as a “facilitator of innovation,” supporting early-stage development and leveraging real-world data at home,…

Denmark Having become Europe’s number one pharma success story thanks largely to its blockbuster weight-loss drug, Wegovy, Novo Nordisk has been hit with stiff competition from Lilly and seen a steep decline in market performance. The Danish drugmaker has moved to oust its longstanding CEO and is looking to regain lost…

Italy Banking on three key therapeutic areas, including a newly established rare disease franchise, the Italian midcap Chiesi has pursued a sweeping transformation in recent years. In its reboot efforts, the company has not only made significant R&D investments, but pursued key M&A and partnership deals, and aimed for global expansion.…

Global 2023 may have been a breakthrough year for cell and gene therapies with the FDA approving a record of seven novel treatments, but 2024 did not fall behind in the number of greenlit therapies. With seven new approvals and three expanded indications, the cell and gene therapies authorized by the…

Global As the neuroscience field gains unprecedented momentum, Roche is taking a leading role in redefining how neurodegenerative diseases like Alzheimer’s are understood, diagnosed, and treated. Dr Azad Bonni, Senior Vice President and Global Head of Neuroscience and Rare Diseases at Roche’s Pharma Research and Early Development (pRED), brings a unique…

Germany After February’s snap election that brought Friedrich Merz to power, a coalition between his conservative CDU/CSU bloc and the centre-left SPD has outlined an agreement this month that will serve as the framework for the new German government’s healthcare agenda . While the accord presents broad healthcare reforms, the key…